ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Elicio Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.55−0.01 (-0.64%)
Close on Oct 19, 2026
- Market cap
- $29.83M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
14.9%
4M of 26M shares
Institutional holders
48
24 new, 23 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Yekaterina Chudnovsky | 9,764,864 | 48.00% | 13D (active) amendment | Jun 3, 2025 |
| Knoll Capital Management, LLC | 630,915 | 5.20% | 13G (passive) | Jan 30, 2025 |
| Moti Investments LLC | 1,408,892 | 6.10% | 13G (passive) | Jul 1, 2026 |
| Gakasa Holdings, LLC | 1,211,957 | 5.30% | 13G (passive) amendment | Jul 1, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ELTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 1,211,957 | 4.61% | $4.74M | +581,042 | 2.64% |
| BlackRock, Inc. | 766,005 | 2.91% | $3.00M | +715,408 | 0.00% |
| Vanguard Capital Management LLC | 572,151 | 2.18% | $2.24M | +53,513 | 0.00% |
| Geode Capital Management, LLC | 311,354 | 1.18% | $1.22M | +176,190 | 0.00% |
| State Street Corp | 179,420 | 0.68% | $701.53K | +128,800 | 0.00% |
| Northern Trust Corp | 130,162 | 0.50% | $508.93K | +70,428 | 0.00% |
| Ikarian Capital, LLC | 100,000 | 0.38% | $391.00K | New | 0.04% |
| Vanguard Portfolio Management LLC | 88,905 | 0.34% | $347.62K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 88,062 | 0.34% | $344.32K | +18,873 | 0.00% |
| Alliancebernstein L.P. | 81,280 | 0.31% | $317.81K | New | 0.00% |
| UBS Group AG | 40,419 | 0.15% | $158.04K | +6,650 | 0.00% |
| Charles Schwab Investment Management Inc | 31,706 | 0.12% | $123.97K | New | 0.00% |
| Boothbay Fund Management, LLC | 30,690 | 0.12% | $120.00K | New | 0.00% |
| Morgan Stanley | 25,546 | 0.10% | $99.89K | −6,858 | 0.00% |
| Leonteq Securities AG | 20,000 | 0.08% | $78.20K | New | 0.00% |
| Nuveen, LLC | 17,888 | 0.07% | $69.94K | New | 0.00% |
| Citigroup Inc | 17,726 | 0.07% | $69.31K | New | 0.00% |
| Bank of New York Mellon Corp | 15,884 | 0.06% | $62.11K | New | 0.00% |
| New York State Common Retirement Fund | 14,200 | 0.05% | $55.52K | New | 0.00% |
| Meyer Handelman Co | 13,899 | 0.05% | $54.35K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 48 | 4M | 14.9% | 24 / 14 | 3 / 23 | 2M | 1M |
| Q1 2026 | 47 | 3M | 10.0% | 19 / 13 | 6 / 7 | 1M | 0M |
| Q4 2025 | 37 | 2M | 7.9% | 13 / 10 | 5 / 4 | 0M | 0M |
| Q3 2025 | 28 | 2M | 7.3% | 10 / 9 | 2 / 3 | 1M | 0M |
| Q2 2025 | 21 | 1M | 5.5% | 3 / 5 | 5 / 6 | 0M | 0M |
| Q1 2025 | 24 | 2M | 6.1% | 9 / 8 | 2 / 2 | 1M | 0M |
| Q4 2024 | 17 | 0M | 1.7% | 2 / 2 | 7 / 3 | 0M | 0M |
| Q3 2024 | 18 | 0M | 1.9% | 4 / 6 | 1 / 4 | 0M | 0M |
| Q2 2024 | 20 | 1M | 2.5% | 5 / 7 | 2 / 3 | 0M | 0M |
| Q1 2024 | 18 | 0M | 1.5% | 4 / 5 | 2 / 4 | 0M | 0M |
| Q4 2023 | 18 | 0M | 1.3% | 2 / 6 | 4 / 2 | 0M | 0M |
| Q3 2023 | 18 | 0M | 1.3% | 3 / 6 | 3 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ELTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 415,401 | 1.58% | $1.62M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 318,753 | 1.21% | $1.25M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 143,596 | 0.55% | $561.46K | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 139,731 | 0.53% | $391.25K | 0.00% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 121,695 | 0.46% | $475.83K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 58,434 | 0.22% | $668.48K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 43,717 | 0.17% | $170.93K | 0.01% | Jun 30, 2026 |
| EQ/Small Company Index Portfolio | 40,640 | 0.15% | $158.90K | 0.01% | Jun 30, 2026 |
| EQ/AB Small Cap Growth Portfolio | 40,640 | 0.15% | $158.90K | 0.01% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 31,706 | 0.12% | $88.78K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 29,434 | 0.11% | $115.09K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 21,289 | 0.08% | $243.55K | 0.00% | May 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 17,888 | 0.07% | $50.09K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 16,617 | 0.06% | $190.10K | 0.00% | May 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 16,449 | 0.06% | $64.32K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert Connelly | CEO, President and Director | 120,570 | 0.46% | Jul 17, 2026 |
| Peter DeMuth | Chief Scientific Officer | 21,543 | 0.08% | Jul 17, 2026 |
| Christopher Haqq | See Remarks | 57,381 | 0.22% | Jul 17, 2026 |
| Preetam Shah | See Remarks | 24,000 | 0.09% | Jul 17, 2026 |
| Jay Venkatesan | Director | 180,534 | 0.69% | Sep 2, 2026 |
| Karen J. Wilson | Director | 18,718 | 0.07% | Sep 2, 2026 |
| Robert R. Ruffolo | Director | – | – | Sep 2, 2026 |
| Yekaterina Chudnovsky | Director, 10% owner | 5,416,212 | 20.61% | Sep 2, 2026 |
| Allen Nissenson | Director | 9,383 | 0.04% | Sep 2, 2026 |
| Carol Gail Ashe | Director | – | – | Sep 2, 2026 |
| Julian Adams | Director | – | – | Sep 2, 2026 |
| Gkcc, Llc | 10% owner | 1,915,639 | 7.29% | Jun 4, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Peter DeMuth Chief Scientific Officer | Feb 2, 2026 | Award | +20,800 | – | – | 21,543 |
| Christopher Haqq See Remarks | Feb 2, 2026 | Award | +25,400 | – | – | 57,381 |
| Robert Connelly CEO, President and Director | Feb 2, 2026 | Award | +73,600 | – | – | 120,570 |
| Preetam Shah See Remarks | Feb 2, 2026 | Award | +24,000 | – | – | 24,000 |
| Peter DeMuth Chief Scientific Officer | Dec 9, 2025 | Option exercise | +362 | $4.41 | $1.60K | 743 |
| Yekaterina Chudnovsky Director, 10% owner | Mar 5, 2025 | Conversion | +3,500,573 | $5.81 | $20.34M | 5,416,212 |
| Peter DeMuth Chief Scientific Officer | Dec 16, 2024 | Option exercise | +381 | $4.41 | $1.68K | 381 |
| Jay Venkatesan Director | Nov 26, 2024 | Option exercise | +50,000 | $0.01 | $500 | 179,581 |
| Gkcc, Llc 10% owner | Dec 22, 2023 | Buy | +1,213,000 | $5.81 | $7.05M | 1,915,639 |
| Itzhak Goldberg Director | Jul 1, 2022 | Tax withholding | −32,082 | $1.12 | $35.93K | 1,687,986 |
| Jay Venkatesan See Remarks, Director | May 25, 2022 | Buy | +11,313 | $1.25 | $14.14K | 1,891,947 |
| Jay Venkatesan See Remarks, Director | May 24, 2022 | Buy | +32,200 | $1.24 | $39.93K | 1,721,457 |
| Jay Venkatesan See Remarks, Director | May 20, 2022 | Buy | +50,000 | $1.23 | $61.50K | 1,689,257 |
| Allen Nissenson Director | May 20, 2022 | Buy | +2,037 | $1.18 | $2.40K | 9,383 |
| Allen Nissenson Director | May 19, 2022 | Buy | +7,346 | $1.16 | $8.52K | 7,346 |
| Jay Venkatesan See Remarks, Director | Dec 28, 2021 | Buy | +210,337 | $2.66 | $559.50K | 1,639,257 |
| Jay Venkatesan See Remarks, Director | Dec 27, 2021 | Buy | +66,907 | $2.55 | $170.61K | 1,428,920 |
| Jay Venkatesan See Remarks, Director | Dec 20, 2021 | Buy | +3,527 | $2.54 | $8.96K | 1,362,013 |
| John F. Neylan See Remarks | Dec 20, 2021 | Sale(10b5-1 plan) | −358 | $2.62 | $938 | 35,136 |
| Jay Venkatesan See Remarks, Director | Dec 17, 2021 | Buy | +13,742 | $2.54 | $34.90K | 1,358,486 |
| Jay Venkatesan See Remarks, Director | Dec 16, 2021 | Buy | +27,883 | $2.55 | $71.10K | 1,344,744 |
| Jay Venkatesan See Remarks, Director | Dec 15, 2021 | Buy | +77,604 | $2.41 | $187.03K | 1,316,861 |
| Gregory S. Curhan See Remarks | Dec 15, 2021 | Buy | +4,000 | $2.37 | $9.48K | 4,000 |
| Jennifer J. Rhodes See Remarks | Dec 14, 2021 | Sale(10b5-1 plan) | −451 | $2.42 | $1.09K | 30,399 |
| Itzhak Goldberg See Remarks, Director | Dec 6, 2021 | Sale(10b5-1 plan) | −32,118 | $3.35 | $107.60K | 1,720,068 |
| Itzhak Goldberg See Remarks, Director | Dec 3, 2021 | Sale(10b5-1 plan) | −40,215 | $3.39 | $136.33K | 1,752,186 |
| Itzhak Goldberg See Remarks, Director | Dec 2, 2021 | Sale(10b5-1 plan) | −38,800 | $3.51 | $136.19K | 1,792,401 |
| Itzhak Goldberg See Remarks, Director | Dec 1, 2021 | Sale(10b5-1 plan) | −38,867 | $3.54 | $137.59K | 1,831,201 |
| John F. Neylan See Remarks | Nov 18, 2021 | Sale(10b5-1 plan) | −374 | $4.13 | $1.54K | 35,494 |
| Itzhak Goldberg See Remarks | Nov 16, 2021 | Sale(10b5-1 plan) | −38,495 | $4.26 | $163.99K | 1,870,068 |
| Itzhak Goldberg See Remarks | Nov 15, 2021 | Sale(10b5-1 plan) | −111,505 | $4.17 | $464.98K | 1,908,563 |
| Jennifer J. Rhodes See Remarks | Nov 15, 2021 | Sale(10b5-1 plan) | −433 | $4.40 | $1.91K | 30,850 |
| John F. Neylan See Remarks | Oct 18, 2021 | Sale(10b5-1 plan) | −373 | $8.62 | $3.22K | 35,868 |
| Jennifer J. Rhodes See Remarks | Oct 14, 2021 | Sale(10b5-1 plan) | −430 | $8.65 | $3.72K | 31,283 |
| John F. Neylan See Remarks | Sep 20, 2021 | Sale(10b5-1 plan) | −376 | $10.07 | $3.79K | 36,241 |
| Jennifer J. Rhodes See Remarks | Sep 14, 2021 | Sale(10b5-1 plan) | −430 | $10.64 | $4.58K | 31,713 |
| Llc Eisa-Abc 10% owner | Aug 31, 2021 | Other | −913,659 | – | – | 2,740,978 |
| John F. Neylan See Remarks | Aug 18, 2021 | Sale(10b5-1 plan) | −381 | $9.03 | $3.44K | 36,617 |
| Jennifer J. Rhodes See Remarks | Aug 16, 2021 | Sale(10b5-1 plan) | −445 | $10.68 | $4.75K | 32,143 |
| Jennifer J. Rhodes See Remarks | Jul 21, 2021 | Sale(10b5-1 plan) | −432 | $10.94 | $4.73K | 32,588 |
| John F. Neylan See Remarks | Jul 21, 2021 | Sale(10b5-1 plan) | −365 | $10.98 | $4.01K | 36,998 |
| Jennifer J. Rhodes See Remarks | Jul 14, 2021 | Sale(10b5-1 plan) | −431 | $11.01 | $4.75K | 32,589 |
| Jay Venkatesan See Remarks, Director | Jun 24, 2021 | Tax withholding | −41,091 | $13.78 | $566.23K | 1,239,257 |
| Itzhak Goldberg See Remarks | Jun 24, 2021 | Tax withholding | −47,410 | $13.78 | $653.31K | 2,020,068 |
| John F. Neylan See Remarks | Jun 18, 2021 | Sale(10b5-1 plan) | −366 | $13.20 | $4.83K | 37,363 |
| Jennifer J. Rhodes See Remarks | Jun 14, 2021 | Sale(10b5-1 plan) | −427 | $13.27 | $5.67K | 33,020 |
| John F. Neylan See Remarks | May 18, 2021 | Sale(10b5-1 plan) | −363 | $13.91 | $5.05K | 37,729 |
| Jennifer J. Rhodes See Remarks | May 14, 2021 | Sale(10b5-1 plan) | −440 | $13.92 | $6.12K | 33,447 |
| John F. Neylan See Remarks | Apr 19, 2021 | Sale(10b5-1 plan) | −381 | $13.55 | $5.16K | 38,092 |
| Jennifer J. Rhodes See Remarks | Apr 15, 2021 | Sale | −399 | $15.01 | $5.99K | 33,887 |
| John F. Neylan See Remarks | Mar 17, 2021 | Sale | −442 | $19.13 | $8.46K | 38,453 |
| Jennifer J. Rhodes See Remarks | Mar 13, 2021 | Sale | −499 | $20.45 | $10.20K | 34,286 |
| Jennifer J. Rhodes See Remarks | Feb 13, 2021 | Sale | −457 | $19.54 | $8.93K | 34,785 |
| Victor F. Ganzi Director | Feb 9, 2021 | Sale | −246,720 | $16.00 | $3.95M | 823,117 |
| Victor F. Ganzi Director | Feb 9, 2021 | Option exercise | +614,310 | $6.43 | $3.95M | 1,069,837 |
| Jay Venkatesan See Remarks, Director | Feb 9, 2021 | Conversion | +262 | $11.57 | $3.03K | 1,439,525 |
| Jay Venkatesan See Remarks, Director | Feb 9, 2021 | Sale | −159,177 | $16.00 | $2.55M | 1,367,263 |
| Jay Venkatesan See Remarks, Director | Feb 9, 2021 | Option exercise | +396,329 | $6.43 | $2.55M | 1,598,440 |
| Victor F. Ganzi Director | Feb 9, 2021 | Sale | −246,720 | $16.00 | $3.95M | 576,397 |
| Victor F. Ganzi Director | Feb 9, 2021 | Option exercise | +367,590 | $6.43 | $2.36M | 823,117 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.